1403 studies found for:    "Liver Neoplasms"
Show Display Options
Rank Status Study
21 Active, not recruiting Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Biological: cixutumumab;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
22 Terminated AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacological study
23 Terminated Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sunitinib malate;   Drug: capecitabine
24 Recruiting Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: placebo;   Other: laboratory biomarker analysis
25 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
26 Completed Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: bortezomib;   Other: laboratory biomarker analysis
27 Completed Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
28 Completed Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis
29 Completed Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Intervention: Drug: belinostat
30 Withdrawn Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Intervention: Radiation: stereotactic body radiation therapy
31 Recruiting Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Radiation: yttrium Y 90 glass microspheres;   Other: laboratory biomarker analysis
32 Recruiting Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot be Removed by Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: tivozanib;   Other: pharmacological study;   Other: laboratory biomarker analysis
33 Terminated MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
34 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Intervention: Radiation: stereotactic body radiation therapy
35 Completed Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
36 Recruiting PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Stage D Adult Primary Liver Cancer (BCLC);   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: PET scan;   Procedure: CT Scan;   Procedure: hepatic artery embolization
37 Terminated BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
Conditions: Adult Primary Cholangiocellular Carcinoma;   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Extrahepatic Bile Duct Cancer;   Localized Gallbladder Cancer;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: ixabepilone;   Other: laboratory biomarker analysis
38 Active, not recruiting Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: dasatinib;   Other: pharmacological study
39 Terminated EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Conditions: Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Fallopian Tube Cancer;   Gastrointestinal Stromal Tumor;   Localized Extrahepatic Bile Duct Cancer;   Localized Gallbladder Cancer;   Localized Gastrointestinal Carcinoid Tumor;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Colon Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Small Intestine Cancer;   Recurrent Uterine Sarcoma;   Regional Gastrointestinal Carcinoid Tumor;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage 0 Non-small Cell Lung Cancer;   Stage I Adult Soft Tissue Sarcoma;   Stage I Colon Cancer;   Stage I Gastric Cancer;   Stage I Non-small Cell Lung Cancer;   Stage I Ovarian Epithelial Cancer;   Stage I Ovarian Germ Cell Tumor;   Stage I Pancreatic Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage II Colon Cancer;   Stage II Gastric Cancer;   Stage II Non-small Cell Lung Cancer;   Stage II Ovarian Epithelial Cancer;   Stage II Ovarian Germ Cell Tumor;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage II Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Colon Cancer;   Stage III Gastric Cancer;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Uterine Sarcoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: EF5;   Drug: motexafin lutetium;   Other: pharmacological study
40 Terminated Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
Conditions: Cancer;   Liver Cancer;   Primary Liver Cancer;   Hepatocellular Carcinoma;   Hepatoma
Interventions: Drug: PI-88;   Drug: placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years